Related Experiment Video
Updated: Jun 10, 2025

Simple and Fast Rolling Circle Amplification-Based Detection of Topoisomerase 1 Activity in Crude Biological Samples
Published on: December 2, 2022
Aclarubicin Reduces the Nuclear Mobility of Human DNA Topoisomerase IIβ
Keiko Morotomi-Yano1, Ken-Ichi Yano1,2
1Institute of Industrial Nanomaterials, Kumamoto University, Kumamoto 860-8555, Japan.
Abstract:
DNA topoisomerase II (TOP2) is an enzyme that resolves DNA topological problems arising in various nuclear processes, such as transcription. Aclarubicin, a member of the anthracyclines, is known to prevent the association of TOP2 with DNA, inhibiting the early step of TOP2 catalytic reactions. During our research on the subnuclear distribution of human TOP2B, we found that aclarubicin affects the mobility of TOP2B in the nucleus. FRAP analysis demonstrated that aclarubicin decreased the nuclear mobility of EGFP-tagged TOP2B in a concentration-dependent manner. Aclarubicin exerted its inhibitory effects independently of TOP2B enzymatic activities: TOP2B mutants defective for either ATPase or topoisomerase activity also exhibited reduced nuclear mobility in the presence of aclarubicin. Immunofluorescence analysis showed that aclarubicin antagonized the induction of DNA damage by etoposide. Although the prevention of the TOP2-DNA association is generally considered a primary action of aclarubicin in TOP2 inhibition, our findings highlight a previously unanticipated effect of aclarubicin on TOP2B in the cellular environment.
Insights
Aclarubicin, an anthracycline, unexpectedly reduces the nuclear mobility of DNA topoisomerase II beta (TOP2B), independent of its enzymatic activity. This finding reveals a novel cellular effect of aclarubicin on TOP2B.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- DNA topoisomerase II (TOP2) enzymes are crucial for resolving DNA topological issues during transcription and other nuclear processes.
- Aclarubicin, an anthracycline, is known to inhibit TOP2 by preventing its association with DNA, affecting early catalytic steps.
Purpose of the Study:
- To investigate the effect of aclarubicin on the subnuclear distribution and mobility of human TOP2B.
- To elucidate the mechanism underlying aclarubicin's impact on TOP2B function in the cellular environment.
Main Methods:
- Fluorescence Recovery After Photobleaching (FRAP) analysis to assess EGFP-tagged TOP2B nuclear mobility.
- Utilized TOP2B mutants defective in ATPase or topoisomerase activity.
- Immunofluorescence analysis to evaluate DNA damage induction by etoposide.
Main Results:
- Aclarubicin significantly decreased the nuclear mobility of EGFP-tagged TOP2B in a concentration-dependent manner.
- This reduction in mobility occurred independently of TOP2B's ATPase or topoisomerase enzymatic activities.
- Aclarubicin was found to antagonize etoposide-induced DNA damage.
Conclusions:
- Aclarubicin exhibits a previously unrecognized effect on TOP2B nuclear mobility within the cell.
- The drug's impact on TOP2B mobility is distinct from its known inhibition of TOP2-DNA association.
- These findings offer new insights into aclarubicin's cellular actions beyond its direct enzymatic inhibition.
Related Concept Videos
Drugs that Destabilize Microtubules
Drugs that Stabilize Microtubules
DNA Topoisomerases
Types and Mechanism of action
Topoisomerases are divided into two main types. ...
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Destabilization of Microtubules
Anaphase Promoting Complex

